Document Type
Article
Department
Paediatrics and Child Health
Abstract
Ofatumumab is a monoclonal antibody that reduces the level of B cells that alter the progression of relapsing multiple sclerosis. Originally approved by the Food and Drug Administration (FDA) in August 2020, this meta-analysis determines the outcomes of four randomized controlled trials (RCTs) for endline outcomes of Gadolinium-enhancing T1 lesions on MRI scans reported as Cohen's d and relapse rate reported as risk ratio. All four RCTs reported favorable findings of gadolinium-enhancing T1 lesions (Cohen's d = -0.44, p < 0.00001). The relapse rate was reduced by 46% post ofatumumab administration (RR = 0.54, p < 0.00001). With 14 ongoing trials in this area, more data is required to consolidate our findings.
Publication (Name of Journal)
Healthcare (Basel, Switzerland)
Recommended Citation
Taj, H. M.,
Talib, M.,
Siddiqa, S.,
Sarfraz, A.,
Sarfraz, Z.,
Robles-Velasco, K.,
Cherrez-Ojeda, I.
(2022). What do we know so far about ofatumumab for relapsing multiple sclerosis? A meta-analytical study. Healthcare (Basel, Switzerland), 10(11).
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/1259
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Included in
Cells Commons, Nervous System Diseases Commons, Neurology Commons, Neurosurgery Commons, Radiology Commons
Comments
Pagination are not provided by the author/publisher